HC Wainwright Weighs in on Xeris Biopharma Q1 Earnings

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) – Research analysts at HC Wainwright issued their Q1 2025 earnings per share estimates for Xeris Biopharma in a research report issued on Friday, March 7th. HC Wainwright analyst O. Livnat anticipates that the company will earn ($0.08) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $8.00 target price on the stock. The consensus estimate for Xeris Biopharma’s current full-year earnings is ($0.41) per share. HC Wainwright also issued estimates for Xeris Biopharma’s Q2 2025 earnings at ($0.06) EPS, Q3 2025 earnings at ($0.01) EPS, Q4 2025 earnings at $0.01 EPS and FY2029 earnings at $0.78 EPS.

A number of other analysts have also weighed in on XERS. Jefferies Financial Group reaffirmed a “buy” rating and set a $6.00 price objective (up previously from $4.00) on shares of Xeris Biopharma in a research report on Wednesday, January 29th. Leerink Partners increased their target price on Xeris Biopharma from $5.00 to $6.00 and gave the company an “outperform” rating in a report on Friday, March 7th. Craig Hallum increased their target price on Xeris Biopharma from $5.00 to $6.50 and gave the company a “buy” rating in a report on Friday, March 7th. Finally, Piper Sandler reissued a “neutral” rating and issued a $4.00 target price (up previously from $3.00) on shares of Xeris Biopharma in a report on Friday, March 7th. One analyst has rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $5.92.

Xeris Biopharma Trading Down 4.4 %

Xeris Biopharma stock opened at $4.39 on Monday. Xeris Biopharma has a twelve month low of $1.69 and a twelve month high of $4.68. The stock’s fifty day simple moving average is $3.61 and its 200-day simple moving average is $3.28. The firm has a market capitalization of $654.47 million, a P/E ratio of -9.76 and a beta of 2.32.

Hedge Funds Weigh In On Xeris Biopharma

Several large investors have recently bought and sold shares of the business. Mackenzie Financial Corp boosted its stake in Xeris Biopharma by 446.0% in the fourth quarter. Mackenzie Financial Corp now owns 129,952 shares of the company’s stock valued at $441,000 after acquiring an additional 106,153 shares in the last quarter. Squarepoint Ops LLC boosted its stake in Xeris Biopharma by 118.2% in the fourth quarter. Squarepoint Ops LLC now owns 40,769 shares of the company’s stock valued at $138,000 after acquiring an additional 22,084 shares in the last quarter. Two Sigma Advisers LP acquired a new position in Xeris Biopharma in the fourth quarter valued at $47,000. Stonepine Capital Management LLC acquired a new position in Xeris Biopharma in the fourth quarter valued at $618,000. Finally, Sherbrooke Park Advisers LLC acquired a new position in Xeris Biopharma in the fourth quarter valued at $79,000. Hedge funds and other institutional investors own 42.75% of the company’s stock.

Xeris Biopharma Company Profile

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.